EGFR and non-small cell lung carcinoma: Strikingly, a great number of these studies were done in NSCLC cell lines that did not carry EGFR‐TKI–sensitive mutations (thus making the outcomes less relevant), and the role of autophagy in acquired resistance to first‐line EGFR‐TKI treatment was poorly addressed in TKI‐sensitive cells.